Lantheus Holdings, Inc. (LNTH)
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.
Why Lantheus Holdings Stock Is Skyrocketing Today
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
Lantheus Stock Gets A Radioactive Surge On Medicare Proposal
Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for May 31st
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"
Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade
The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
